Patterns of publicly funded naltrexone use among patients diagnosed with alcohol use disorder in Ontario
Tourchian N, McCormack D, Leece P, Tadrous M, Gomes T. Alcohol Alcohol. 2024; 59(2):agad091. Epub 2024 Jan 31.
Publications
Impact of COVID-19 pandemic on prescription stimulant use among children and youth: a population-based study
Antoniou T, Pajer K, Gardner W, Penner M, Lunsky Y, McCormack D, Tadrous M, Mamdani M, Gozdyra P, Juurlink DN, Gomes T. Eur Child Adolesc Psychiatry. 2024; Jan 5 [Epub ahead of print].
Opioid agonist treatment retention among people initiating methadone and buprenorphine across diverse demographic and geographic subgroups in Ontario: a population-based retrospective cohort study
Elnagdi A, McCormack D, Bozinoff N, Tadrous M, Antoniou T, Munro C, Campbell T, Paterson JM, Mamdani M, Sproule B, Gomes T. Can J Addict. 2023; 14(4):p 44-54. Epub 2023 Dec 29.
Virtual visits with own family physician vs outside family physician and emergency department use
Lapointe-Shaw L, Salahub C, Austin PC, Bai L, Bhatia RS, Bird C, Glazier RH, Hedden L, Ivers NM, Martin D, Shuldiner J, Spithoff S, Tadrous M, Kiran T. JAMA Netw Open. 2023; 6(12):e2349452. Epub 2023 Dec 27.
Protection conferred by COVID-19 vaccination, prior SARS-CoV-2 infection, or hybrid immunity against Omicron-associated severe outcomes among community-dwelling adults
Lee N, Nguyen L, Austin PC, Brown KA, Grewal R, Buchan SA, Nasreen S, Gubbay J, Schwartz KL, Tadrous M, Wilson K, Wilson SE, Kwong JC. Clin Infect Dis. 2024; Nov 24 {Epub ahead of print].
Characteristics, treatment patterns and retention with extended-release subcutaneous buprenorphine for opioid use disorder: a population-based cohort study in Ontario, Canada
Iacono A, Wang T, Tadrous M, Campbell T, Kolla G, Leece P, Sproule B, Kleinman RA, Besharah J, Munro C, Doolittle M, Gomes T. Drug and Alcohol Depend. 2023; Nov 19 [Epub ahead of print].
Newborn and early infant outcomes following maternal COVID-19 vaccination during pregnancy
Jorgensen S, Drover S, Fell D, Austin P, D’Souza R, Guttmann A, Buchan S, Wilson S, Nasreen S, Schwartz K, Tadrous M, Wilson K, Kwong J. JAMA Pediatr. 2023; Oct 23 [Epub ahead of print].
Impact of a publicly-funded pharmacare program policy on benzodiazepine dispensing among children and youth: a population-based natural experiment
Antoniou T, McCormack D, Kitchen S, Pajer K, Gardner W, Lunsky Y, Penner M, Tadrous M, Mamdani M, Juurlink DN, Gomes T. BMC Pediatr. 2023; 23(1):519. Epub 2023 Oct 19.
Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged ≥50 years in Ontario, Canada: a Canadian Immunization Research Network (CIRN) study
Grewal R, Buchan SA, Nguyen L, Nasreen S, Austin PC, Brown KA, Gubbay J, Lee N, Schwartz KL, Tadrous M, Wilson K, Wilson SE, Kwong JC. J Infect Dis. 2023; Oct 5 [Epub ahead of print].
Examining the impact of COVID-19 on healthcare utilization among persons with chronic spinal cord injury/dysfunction: a population study
Senthinathan A, Tadrous M, Hussain S, Craven BC, Jaglal SB, Moineddin R, Shepherd J, Cadel L, Noonan VK, McKay S, Tu K, Guilcher SJT. Spinal Cord. 2023; Sep 2 [Epub ahead of print].